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Abstract
INTRODUCTION: Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology which 
affects mainly children <5 years of age. If the disease is left untreated, it can lead to serious complications such as 
inflammation of the blood vessels. 
AIM: We aim to evaluate the clinical and laboratory findings and response to therapy of KD at Hue Central Hospital.
METHODS: This is a retrospective study of patients with KD at Pediatric Center of Hue Central Hospital between 
January 2010 and December 2019. Clinical and laboratory examinations as well as the echocardiograms finding 
were analyzed.
RESULTS: All patients were under 5 years old, in which boys were more than girls. Fever lasting over 5 days, 
changing in the mouth mucosa, and peripheral extremities were seen in all patients. About 73.2% had bilateral 
conjunctivitis and 78.0% had rash. About 42.3% of patients had cervical lymphadenopathy. Laboratory findings were 
noted with 84.5% of patients had hyperleukocytosis (>12,000/ mm3), 76.2% of patients had high serum C-reactive 
protein (CRP) levels (>100 mg/dl), 56% of patients had erythrocyte sediment rate >60 mm in the 1st h, and 34.5% 
of patients had thrombocytosis (platelet count >500,000/mm3) at the time of diagnosis. About 26.2% of patients had 
coronary artery lesions. Most patients (84.4%) had good outcome since the first dose of gamma-globulin and 13% 
of patients needed the second dose. There was a significant correlation between coronary artery abnormalities and 
no or late treatment of gamma-globulin.
CONCLUSION: KD was very common in children under 5 years old with the high rate of coronary artery lesion. 
Treatment with gamma-globulin on or before 10 days of fever resulted in better coronary outcomes and decreased 
the total length of time of clinical symptoms.
Edited by: Ksenija Bogoeva-Kostovska
Citation: Xuan NM, Hao TK, Anh NTH. A Retrospective 
Cohort Study of Kawasaki Disease in Hue Central 
Hospital for 10 Years (2010–2019). Open Access 
Maced J Med Sci. 2020 Apr 10; 8(B):99-103. https://doi.
org/10.3889/oamjms.2020.3858
Keywords: Kawasaki disease; Gammaglobulin; 
Complication
*Correspondence: Tran Kiem Hao, Pediatric 
Center, Hue Central Hospital, 16 Le Loi Street, 
Hue City, Vietnam. Phone: +84914002329. 
E-mail: trankiemhaobvh@yahoo.com
Received: 08-Oct-2019
Revised: 06-Mar-2020
Accepted: 18-Mar-2020
Copyright: © 2020 Ngo Minh Xuan, Tran Kiem Hao, 
Nguyen Thi Hoang Anh
Funding: This research did not receive any financial 
support
Competing Interests: The authors have declared that no 
competing interest exists
Open Access: This is an open-access article distributed 
under the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 4.0)
Introduction
Kawasaki disease (KD), or mucocutaneous 
lymph node syndrome, was first described in Japan 
in 1967 by doctor Tomisaku Kawasaki [1]. It has 
been reported in almost every country of the world, 
particularly it occurs most commonly in children of 
Asian descent [2]. Up to 25% of untreated children 
will develop coronary artery dilatation and may lead 
to ischemic heart disease, myocardial infarction, or 
even sudden death [3], but therapy with intravenous 
immunoglobulin (IVIG) and aspirin within the first 10 
days of fever onset reduces the prevalence of coronary 
artery abnormalities to approximately 5% [4].
In Vietnam, KD was first reported at the National 
Pediatric Hospital in 1995 and has been popular in almost 
parts of the country recently. Although no overall data 
of the prevalence of KD in the whole of Vietnam were 
established, some sporadic studies showed the rate of 
cardiovascular abnormalities in KD up to 39.2% [5].
Diagnosis is made difficult by the fact that these 
symptoms are not usually all present at the same time; 
the only persistent symptom is fever [6]. Furthermore, it is 
commonly misdiagnosed as a viral exanthem. Symptoms 
that point to a diagnosis other than KD include exudative 
conjunctivitis, exudative pharyngitis, generalized (rather 
than cervical) lymphadenopathy, discrete intraoral 
lesions, and a bullous or vesicular rash [6]. Therefore, 
we aim to evaluate the clinical and laboratory findings 
and response to therapy of KD in Hue Central Hospital.
Methods
This is a retrospective study of patients with 
KD at Pediatric Center of Hue Central Hospital between 
January 2010 and December 2019. The study was 
approved by the Research Ethics Committee of Hue 
Central Hospital (IRB No.: 01012019/HCH) and the 
informed consent was waived.
The study evaluated 168 patients having KD 
diagnosed in accordance with the American Heart 
Association (AHA) criteria [7].
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Complete KD is defined as having fever of ≥5 
days with at least four of the five principal clinical signs: 
1. Bilateral conjunctival injections
2. Changes in the lips and oral cavity
3. Polymorphous exanthema
4. Changes in the peripheral extremities, and
5. Acute non-purulent cervical lymphadenopathy.
Incomplete KD was defined as having fever 
of ≥5 days with three or fewer principal signs, with or 
without cardiac lesions once other KD-like diseases 
with similar findings.
Both complete KD and incomplete KD were 
included in the study. Patients who lost of follow-up 
within the 1st month post-treatment were exclusive.
Clinical and laboratory examinations, as well 
as the echocardiograms, were performed at least twice 
during hospitalization at presentation and within 1 month 
after discharge. Echocardiography was performed by 
the same pediatric cardiologist and using the same 
echo-Doppler apparatus (Philips Envisor).
Coronary artery lesions were defined as ectasia 
when there was coronary arterial dilatation >3 mm in 
children that were younger than 5 years or ≥5 mm in 
children that were 5 years or older, or when the diameter 
was >1.5 times the size of the adjacent coronary artery [8].
Treatment protocol
Patients received IVIG (2 g/kg over 12 h) along 
with high-dose aspirin (100 mg/kg/day divided into four 
doses) during the acute phase, followed by low-dose 
aspirin (10 mg/kg/day), after fever subsides for 48–72 h, 
for 6–8 weeks [9].
Statistical analysis
All calculations were performed using 
the SPSS ver. 16 (SPSS Inc., Chicago, IL, USA). 
Results are presented as mean ± standard deviation 
for quantitative variables and percentages (%) for 
qualitative. The Pearson’s Chi-square test was used 
for categorical variables. p < 0.05 was considered 
statistically significant.
Results
A total of 168 patients were enrolled in our 
study. Of these cases, 111 (66.1%) were boys and 57 
(33.9%) girls with the male-to-female ratio = 1.95:1. The 
mean age was 9.6 ± 4.1 months (range from 4 months 
to 5 years). Table 1 shows the age distribution of the 
patients with KD. Most patients were referred to the 
hospital during March, April, and July (Figure 1).
Table 1: Age distribution of the patients with KD
Age group Number of patients Percentage
<6 months 28 16.7
6–<12 months 73 43.5
1–5 years 67 39.8
Total 168 100
KD: Kawasaki disease.
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Figure 1: Yearly distribution of the Kawasaki disease patients
The most common sign was fever, oral mucosal 
changes, and changes in extremities followed by 
polymorphous exanthem and conjunctivitis. The mean 
body temperature at diagnosis was 38.6 ± 0.9 (°C) 
after a duration of fever for 7.9 ± 2.9 days since onset. 
Fever stopped in 1.8 ± 0.7 days after treatment with 
IVIG. Table 2 shows the clinical manifestations of KD 
patients.
Table 2: Clinical manifestations of KD patients
Clinical manifestations All patients (%)
1. Fever persisting ≥5 days 168 (100)
2. Bilateral bulbar conjunctival injection without exudate 123 (73.2)
3. Changes in lips and oral cavity 168 (100)
Lips cracking 144 (85.7)
Diffuse injection of oral and pharyngeal mucosae 132 (78.5)
Strawberry tongue 148 (88.1)
1. Changes in extremities 168 (100)
Edema of hands, feet 104 (61.9)
Erythema of palms, soles 112 (66.7)
Periungual peeling of fingers, toes in weeks 2 and 3 134 (79.8)
2. Polymorphous exanthem 131 (78.0)
3. Cervical lymphadenopathy (>1.5 cm diameter), usually unilateral 71 (42.3)
KD: Kawasaki disease.
Laboratory findings of the children are 
summarized in Table 3. Most patients had high 
erythrocyte sediment rate (ESR) and white blood cell 
(WBC) with predominance of neutrophils, as well as 
high platelet and C-reactive protein (CRP). One week 
after treatment with IVIG, all the disease blood test 
markers moved to be normalized significantly.
Most patients (130, 84.4%) stopped fever after 
a single dose of IVIG, but there were 24 patients who 
need the second dose of IVIG.
Echocardiographic abnormalities were 
found in 51 (30.3%) patients. Cardiac abnormalities 
consisted of aneurysm of coronary artery 
(44 patients), pericardial effusion (5 patients), and 
mild mitral regurgitation (2 patients). Table 4 shows 
the characteristics of these abnormal coronary 
arteries. There was a significant correlation between 
coronary artery abnormalities and no or late treatment 
of IVIG (Table 5).
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The clinical manifestations of KD in Hue 
Central Hospital were very similar to those shown 
in other studies [14], [15], [17]. Fever persisting for 
5 days or longer was still the most frequent clinical 
manifestation of KD followed by changes of lips and 
the least frequent symptom was acute non-purulent 
cervical lymphadenopathy [18].
The clinical diagnosis of KD can be challenging 
and laboratory testing can help the clinician evaluate 
the degree of inflammation and can aid in the diagnosis 
of incomplete KD as outlined by the AHA guidelines [7]. 
However, a clear understanding of the dynamic nature 
of these laboratory values is critical to this process. 
Here, we have comprehensively defined the evolution 
of laboratory values overtime in KD subjects before and 
after IVIG treatment.
Children with KD typically have leukocytosis. 
Many children have a normocytic normochromic 
anemia and platelet counts are usually elevated 
by the end of the 1st week of illness with counts 
exceeding 1 million/mm3 in some cases. Inflammatory 
markers are elevated in nearly all patients with KD. 
Measurements of the ESR are helpful in assessing 
the degree of inflammation at diagnosis and before 
IVIG administration. The analytical values of our 
patients were also similar to those previously 
described [18]. In his original paper describing the 
first 50 cases of KD, Dr. Kawasaki noted that both 
the ESR and CRP were elevated during the initial 
presentation and became normal “within 3–4 weeks” 
although “the timing for resolution was not the same” 
with the CRP returning to normal earlier in the course 
of illness [19]. There was also a “tendency toward” a 
high WBC and “various degrees of left shift observed 
in 41 of the 50 subjects,” a “mild, transient elevation…
of serum ALT,” and Coombs negative anemia for 
34 of 35 cases during the initial presentation [19]. 
Our laboratory data in Table 2 were similar to those 
results.
In the study of Tremoulet et al. [20], many 
subjects who developed coronary artery abnormalities 
were also IVIG resistant and received two doses of 
IVIG, a fact which could explain the increased ESR in 
the subacute and convalescent phases. However, a 
comparison of the convalescent ESR of IVIG resistant 
versus responsive KD subjects with aneurysms did 
not show a difference between the groups, suggesting 
Table 3: Laboratory findings of KD patients at diagnosis and 1 week after treatment
Laboratory findings At diagnosis (n=168) (%) 1 week after treatment (n=168) (%) p-value
Hemoglobin <10 g/dl 147 (87.5) 111 (66.1) <0.001
Hematocrit <35 g/dl 146 (86.9) 120 (71.4) <0.001
White blood cell >12×103/mm3 142 (84.5) 40 (23.8) <0.001
Neutrophil >70% 33 (19.6) 3 (1.8) <0.001
Platelet count <350×103/mm3 44 (26.2) 12 (7.1) <0.001
Platelet count >500×103/mm3 58 (34.5) 90 (53.6) <0.001
Erythrocyte sediment rate >60, mm/1st h 94 (56.0) 62 (36.9) <0.001
C-reactive protein >1000 mg/l 128 (76.2) 30 (17.9) <0.001
Alanine transaminase >100 UI 12 (7.1) 10 (6.0) 0.8517
Aspartate aminotransferase >100 UI 16 (9.5) 12 (7.1) 0.5488
Albumin <35 g/dl 54 (32.1) 28 (16.7) <0.001
KD: Kawasaki disease.
Table 4: Characteristics of coronary artery abnormalities in KD 
(n=44)
Right coronary artery Left coronary artery
Frequency (n, %) 25 (14.9) 44 (26.2)
Diameter (mm) 4.1 ± 1.1 3.9 ± 1.2
KD: Kawasaki disease.
Table 5: Correlation between coronary artery abnormalities 
and IVIG treatment
Coronary artery 
abnormalities (n=44) (%)
Coronary artery 
normal (n=124) (%)
p-value
IVIG untreated 8 (18.2) 6 (4.8) 0.0143
Late IVIG (after 10-day fever) 26 (59.1) 28 (22.6) <0.001
IVIG: Intravenous immunoglobulin.
Discussion
Since the first report of KD in the early 1960s in 
Japan, the disease has now seen almost every country 
of the world, particularly it occurs most commonly in 
children of Asian descent [2]. Although no overall data 
of the prevalence of KD in the whole of Vietnam were 
established, some sporadic studies showed the clinical 
features, laboratory investigation, and the heart lesion 
in patients with KD [5].
KD almost always affects children. Most 
patients are under 5 years old. Boys develop the illness 
more often than girls [2]. In our study (Table 1), 100% 
of children were under 5 years old, of which 60.2% 
were under 1 year old. Boys were nearly 2-fold more 
than girls. This difference by sex was seen in almost 
previous reports [10], [11], [12], [13]. Data from 399 
patients over the 10-year study period were analyzed 
by Sánchez-Manubens [14], revealing that 233 (58.4%) 
had complete KD, 159 (39.8) incomplete KD, and 7 
(1.7%) were considered atypical KD. The mean annual 
incidence was 3.5/105 children <14 years old and 8/105 
children <5 years old (mean age 37 ± 33 months, range 
1.3–191.3). KD was more frequent in boys (59.6%, 
p < 0.001). Outside of the tropical region, Cimaz from 
Italy showed the same result with the disease peaked 
in the first 2 years of life, with 85.5% of cases under 
5 years. Male/female ratio was 1.4:1. The incidence 
rate was 5.7/100,000 children 0–14 years old and 
14.7 for children younger than 5 years. The incidence 
had a seasonal distribution, with higher incidence 
in spring [15]. Similarly, Saundankar from Australia 
reported that male-to-female ratio was 1.7:1 and the 
median age was 3.8 years [16].
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that the higher ESR in subjects with aneurysms was 
due to more inflammation rather than an effect of the 
second dose of IVIG. Failure to normalize markers of 
inflammation in the convalescent phase suggests that 
a subset of patients with aneurysms has persistent 
inflammation that is not well controlled by standard 
therapy. In our study, none of IVIG resistant was found, 
but there were 24 (14.3%) patients need the second 
dose of IVIG. One week after treatment with IVIG, all 
the disease blood test markers moved to be normalized 
significantly.
The percentage of coronary dilation in our 
series was similar (29.2%) to that in other series 
that describe an incidence around 30% of children 
by Z-score criteria (Z>2), even when treated with 
high-dose IVIG regimens within the first 10 days of 
illness [7]. From a total of 625 children with KD in the 
study of [21], coronary aneurysms were detected in 60 
cases (9.6%), and we identified as primary risk factors 
associated with their development, the presence of 
anemia; child’s height below than 103 cm, maximum 
platelets >900,000/mm3, the total duration of fever 
>10 days, and the duration of fever >8 days before 
treatment. In our series, resistance to IVIG treatment 
was found in more than 15% of the cases, with the 
development of aneurysms being more frequent in 
those cases. In the study of Sánchez-Manubens [14], 
patients with IVIG non-responsiveness, need of 
a second IVIG dose, delay of treatment >10th day 
of illness, ages <1 year old and >8 years old, and 
the presence of sterile pyuria, aseptic meningitis, 
abdominal pain, and uveitis at diagnosis were found 
to have higher risk of coronary aneurisms (p < 0.05). 
Contrast to us, some researches outside of tropical 
region showed the lower percentage in coronary 
artery abnormalities. Cimaz reported only 2.2% of 
patients experienced with coronary artery aneurysm. 
Other coronary artery abnormalities were coded in 
1.44% of patients, pericardial involvement in 1.48% 
of patients, myocardial involvement in 1.03%, cardiac 
valve disease in 0.5%, while 0.24% of patients had 
other cardiac complications [15]. Similarly, Saudankar 
showed 16.7% coronary artery ectasia/dilatation and 
6.8% coronary artery aneurysms [16].
The efficacy of IVIG administered in the acute 
phase of KD is well established to reduce the prevalence 
of coronary artery lesion with higher doses given in a 
single infusion having the greatest efficacy [7], [22]. In 
our study, treatment with IVIG was given to 91.7% of 
the patients, in which, we have 35.1% of patients with 
late treatment, being in these cases more likely the 
development of aneurysms.
This retrospective study may have some 
limitations. It did not show the prevalence of KD in Hue 
Central Hospital due to lacking of epidemiology data. 
The number of subjects in this study was small, these 
data may not be representative of the current situation 
in Vietnam.
Conclusion
KD was very common in children under 5 
years old with the high rate of coronary artery lesion. In 
the absence of a specific diagnostic test, the diagnosis 
of KD is mainly based on clinical criteria. Treatment with 
IVIG on or before 10 days of fever resulted in better 
coronary outcomes and decreased the total length of 
time of clinical symptoms.
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